Merck Sharp + Dohme Corp.

Yan Ni

Rose M Cubbon

Yan Li

Peter Peizhi Luo

Pingyu Zhong

Feng Dong

Andrei Alexandrovich Golosov

Jon H Condra

Laurence B Peterson

Xinwei Wang

Mark Hsieh

Weirong Wang

Ayesha Sitlani

Kevin Caili Wang

Shilpa Pandit

Timothy McCabe

Gopalakrishnan Parthasarathy

Stephen Soisson

Noel Byrne

Dale Lewis

Xun Shen

Sharon Lobo

Kevin Caili Wangr

Sujata Sharma

Jun Lu

Antagonists of human proprotein convertase subtilisin-kexin type 9 ('PCSK9') are disclosed. The disclosed antagonists are effective in the inhibition of PCSK9 function and, accordingly, present desirable antagonists for use in the treatment of conditions associated with PCSK9 activity. The present invention also discloses nucleic acid encoding said antagonists, vectors, host cells, and compositions comprising the antagonists. Methods of making PCSK9-specific antagonists as well as methods of using the antagonists for inhibiting or antagonizing PCSK9 function are also disclosed and form important additional aspects of the present disclosure.

AX132 PCSK9 antagonists

AX1 PCSK9 antagonists

Methods of using PCSK9 antagonists More specifically, methods for measuring circulating PCSK9 levels in a biological sample by means of an immunoassay The immunoassay used can be a solid phase immunoassay, such as a dissociation-enhanced lanthanide fluorescence immunoassay utilizing an E07 capture antibody or coating and a G08 or H23 detecting antibody.

PCSK9 immunoassay

Growing community of inventors

Westfield, NJ, United States of America

Yan Ni